R Qayyum, J Adomaityte - J Clin Hypertens, 2006 - interscience.wiley.com In epidemiologic studies, insulin resistance is associated with hypertension.
Thiazolidinediones (TZDs) are antidiabetic agents that decrease insulin
resistance. Multiple clinical trials have evaluated the effect of TZDs on ... Cited by 28 - Related articles - BL Direct - All 4 versions
- ►nursing2008.com E Mannucci, M Monami, C Lamanna, GF … - Diabetes, Obesity and Metabolism, 2008 - pt.wkhealth.com Aim: The aim of this meta-analysis of randomized clinical trials (RCT) was to
assess whether pioglitazone is also associated with increased cardiovascular
risk, as recently reported for rosiglitazone. Methods: RCT of pioglitazone ... Cited by 14 - Related articles - All 6 versions
- ►endojournals.org HV Joffe, RY Kwong, MD Gerhard-Herman, C … - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc Context: Impaired coronary circulatory function predicts cardiovascular events,
the leading cause of death in patients with diabetes mellitus. Aldosterone
causes cardiovascular injury and is not suppressed by chronic angiotensin ... Cited by 11 - Related articles - BL Direct - All 5 versions
AS Kelly, AM Thelen, DR Kaiser, JM … - Vascular Medicine, 2007 - vmj.sagepub.com The thiazolidinediones (TZDs) have emerged as an effective drug class for
glycemic management in patients with type 2 diabetes mellitus (T2DM). Unlike
other anti-diabetic medications such as sulfonylureas (promotion of ... Cited by 10 - Related articles - BL Direct - All 2 versions
- ►onlinejacc.org RP Naoumova, H Kindler, L Leccisotti, M … - Journal of the American College of Cardiology, 2007 - Elsevier Thiazolidinediones were found to improve insulin sensitivity and MGU in type 2
diabetes and MBF in Mexican Americans with insulin resistance. Familial combined
hyperlipidemia is a complex genetic disorder conferring a high risk of ... Cited by 6 - Related articles - BL Direct - All 11 versions
RB Goldberg - Current Opinion in Endocrinology, Diabetes and …, 2007 - journals.lww.com Recent findings: The thiazolidinedione class improves endothelial vasomotion,
inhibits inflammatory and procoagulant processes and has powerful
antiproliferative and antioxidant effects. Experimentally these agents ... Cited by 4 - Related articles - BL Direct - All 4 versions
SL Norris, S Carson, C Roberts - Update, 2008 - derp.ohsu.edu The purpose of this report is to make available information regarding the
comparative effectiveness and safety profiles of different drugs within
pharmaceutical classes. Reports are not usage guidelines, nor should they ... Cited by 3 - Related articles - View as HTML - All 8 versions
SL Norris, S Carson, C Roberts - Current diabetes reviews, 2007 - ingentaconnect.com Abstract: Objective - To assess the comparative efficacy and safety of
pioglitazone and rosiglitazone. Research design and methods – Multiple
electronic databases were searched for randomized, controlled trials (RCTs) ... Cited by 1 - Related articles - BL Direct - All 3 versions
MOF ACTION - Type 2 Diabetes: Principles and Practice, 2007 - books.google.com MECHANISM OF ACTION The thiazolidinediones are highly selective and potent
agonists for the PPAR-y (Fig. 1) (5, 6). These receptors are important
regulators of adipocyte differentiation, lipid homeostasis, insulin action, ... Related articles - All 2 versions
